Why Did Carlos Slim Buy PBF Energy?
Carlos Slim made a splash in a surprising sector last…
Buy
55
STRM Quote, Financials, Valuation and Earnings
Last price:
$3.92
Seasonality move
:
0.29%
Day range:
$3.65 - $3.85
52-week range:
$1.85 - $9.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.78x
P/B ratio:
1.12x
Volume:
11.9K
Avg. volume:
43.9K
1-year change:
-44.55%
Market cap:
$15.6M
Revenue:
$22.6M
EPS (TTM):
-$2.41
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
STRM
Streamline Health Solutions
|
$5.3M | -- | -24.87% | -- | $22.50 |
|
LENZ
LENZ Therapeutics
|
-- | -$0.40 | -- | -57.13% | -- |
|
LFMD
LifeMD
|
$57.4M | $0.14 | 27.32% | -93.33% | $12.00 |
|
MDRX
Veradigm
|
-- | -- | -- | -- | -- |
|
ORKA
Oruka Therapeutics
|
-- | -$0.98 | -- | -29.53% | $43.17 |
|
TBRG
TruBridge
|
$84.4M | $0.38 | -1.77% | -28.23% | $15.60 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
STRM
Streamline Health Solutions
|
$3.66 | $22.50 | $15.6M | -- | $0.00 | 0% | 0.78x |
|
LENZ
LENZ Therapeutics
|
$28.29 | -- | $778M | -- | $0.00 | 0% | -- |
|
LFMD
LifeMD
|
$5.23 | $12.00 | $226.5M | -- | $0.00 | 0% | 1.08x |
|
MDRX
Veradigm
|
$9.10 | -- | $994.3M | -- | $0.00 | 0% | 0.77x |
|
ORKA
Oruka Therapeutics
|
$19.97 | $43.17 | $698.9M | -- | $0.00 | 0% | -- |
|
TBRG
TruBridge
|
$19.90 | $15.60 | $297M | -- | $0.00 | 0% | 0.84x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
STRM
Streamline Health Solutions
|
46.84% | 3.886 | 128.9% | 0.41x |
|
LENZ
LENZ Therapeutics
|
-- | 3.796 | -- | -- |
|
LFMD
LifeMD
|
173.46% | 3.532 | 8.61% | 0.74x |
|
MDRX
Veradigm
|
-- | 0.334 | -- | -- |
|
ORKA
Oruka Therapeutics
|
-- | 0.000 | -- | -- |
|
TBRG
TruBridge
|
50.52% | 2.010 | 98.74% | 1.38x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
STRM
Streamline Health Solutions
|
$2M | -$2M | -32.78% | -54.79% | -44.81% | -$2M |
|
LENZ
LENZ Therapeutics
|
-- | -$12.9M | -- | -- | -- | -$10.8M |
|
LFMD
LifeMD
|
$48.4M | -$4.7M | -141.04% | -- | -8.78% | $2.7M |
|
MDRX
Veradigm
|
-- | -- | -- | -- | -- | -- |
|
ORKA
Oruka Therapeutics
|
-- | -$29.4M | -- | -- | -- | -- |
|
TBRG
TruBridge
|
$41.5M | $1.9M | -16.31% | -31.4% | 1.87% | $4.8M |
Streamline Health Solutions vs. Competitors
-
Which has Higher Returns STRM or LENZ?
LENZ Therapeutics has a net margin of -56.03% compared to Streamline Health Solutions's net margin of --. Streamline Health Solutions's return on equity of -54.79% beat LENZ Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital STRMStreamline Health Solutions46.03% -$0.61 $26.2M LENZLENZ Therapeutics-- -$0.38 -- -
What do Analysts Say About STRM or LENZ?
Streamline Health Solutions has a consensus price target of $22.50, signalling downside risk potential of -59.02%. On the other hand LENZ Therapeutics has an analysts' consensus of -- which suggests that it could grow by 38.87%. Given that LENZ Therapeutics has higher upside potential than Streamline Health Solutions, analysts believe LENZ Therapeutics is more attractive than Streamline Health Solutions.
Company Buy Ratings Hold Ratings Sell Ratings STRMStreamline Health Solutions1 0 0 LENZLENZ Therapeutics0 0 0 -
Is STRM or LENZ More Risky?
Streamline Health Solutions has a beta of 1.552, which suggesting that the stock is 55.205% more volatile than S&P 500. In comparison LENZ Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock STRM or LENZ?
Streamline Health Solutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENZ Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Streamline Health Solutions pays -- of its earnings as a dividend. LENZ Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STRM or LENZ?
Streamline Health Solutions quarterly revenues are $4.4M, which are larger than LENZ Therapeutics quarterly revenues of --. Streamline Health Solutions's net income of -$2.5M is higher than LENZ Therapeutics's net income of -$10.2M. Notably, Streamline Health Solutions's price-to-earnings ratio is -- while LENZ Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Streamline Health Solutions is 0.78x versus -- for LENZ Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STRMStreamline Health Solutions0.78x -- $4.4M -$2.5M LENZLENZ Therapeutics-- -- -- -$10.2M
-
Which has Higher Returns STRM or LFMD?
LifeMD has a net margin of -56.03% compared to Streamline Health Solutions's net margin of -9.61%. Streamline Health Solutions's return on equity of -54.79% beat LifeMD's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital STRMStreamline Health Solutions46.03% -$0.61 $26.2M LFMDLifeMD90.61% -$0.14 $12.3M -
What do Analysts Say About STRM or LFMD?
Streamline Health Solutions has a consensus price target of $22.50, signalling downside risk potential of -59.02%. On the other hand LifeMD has an analysts' consensus of $12.00 which suggests that it could grow by 129.45%. Given that LifeMD has higher upside potential than Streamline Health Solutions, analysts believe LifeMD is more attractive than Streamline Health Solutions.
Company Buy Ratings Hold Ratings Sell Ratings STRMStreamline Health Solutions1 0 0 LFMDLifeMD7 1 0 -
Is STRM or LFMD More Risky?
Streamline Health Solutions has a beta of 1.552, which suggesting that the stock is 55.205% more volatile than S&P 500. In comparison LifeMD has a beta of 1.491, suggesting its more volatile than the S&P 500 by 49.061%.
-
Which is a Better Dividend Stock STRM or LFMD?
Streamline Health Solutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LifeMD offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Streamline Health Solutions pays -- of its earnings as a dividend. LifeMD pays out -15.08% of its earnings as a dividend.
-
Which has Better Financial Ratios STRM or LFMD?
Streamline Health Solutions quarterly revenues are $4.4M, which are smaller than LifeMD quarterly revenues of $53.4M. Streamline Health Solutions's net income of -$2.5M is higher than LifeMD's net income of -$5.1M. Notably, Streamline Health Solutions's price-to-earnings ratio is -- while LifeMD's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Streamline Health Solutions is 0.78x versus 1.08x for LifeMD. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STRMStreamline Health Solutions0.78x -- $4.4M -$2.5M LFMDLifeMD1.08x -- $53.4M -$5.1M
-
Which has Higher Returns STRM or MDRX?
Veradigm has a net margin of -56.03% compared to Streamline Health Solutions's net margin of --. Streamline Health Solutions's return on equity of -54.79% beat Veradigm's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital STRMStreamline Health Solutions46.03% -$0.61 $26.2M MDRXVeradigm-- -- -- -
What do Analysts Say About STRM or MDRX?
Streamline Health Solutions has a consensus price target of $22.50, signalling downside risk potential of -59.02%. On the other hand Veradigm has an analysts' consensus of -- which suggests that it could grow by 40.11%. Given that Veradigm has higher upside potential than Streamline Health Solutions, analysts believe Veradigm is more attractive than Streamline Health Solutions.
Company Buy Ratings Hold Ratings Sell Ratings STRMStreamline Health Solutions1 0 0 MDRXVeradigm0 0 0 -
Is STRM or MDRX More Risky?
Streamline Health Solutions has a beta of 1.552, which suggesting that the stock is 55.205% more volatile than S&P 500. In comparison Veradigm has a beta of 0.648, suggesting its less volatile than the S&P 500 by 35.152%.
-
Which is a Better Dividend Stock STRM or MDRX?
Streamline Health Solutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veradigm offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Streamline Health Solutions pays -- of its earnings as a dividend. Veradigm pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STRM or MDRX?
Streamline Health Solutions quarterly revenues are $4.4M, which are larger than Veradigm quarterly revenues of --. Streamline Health Solutions's net income of -$2.5M is higher than Veradigm's net income of --. Notably, Streamline Health Solutions's price-to-earnings ratio is -- while Veradigm's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Streamline Health Solutions is 0.78x versus 0.77x for Veradigm. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STRMStreamline Health Solutions0.78x -- $4.4M -$2.5M MDRXVeradigm0.77x -- -- --
-
Which has Higher Returns STRM or ORKA?
Oruka Therapeutics has a net margin of -56.03% compared to Streamline Health Solutions's net margin of --. Streamline Health Solutions's return on equity of -54.79% beat Oruka Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital STRMStreamline Health Solutions46.03% -$0.61 $26.2M ORKAOruka Therapeutics-- -$1.46 -- -
What do Analysts Say About STRM or ORKA?
Streamline Health Solutions has a consensus price target of $22.50, signalling downside risk potential of -59.02%. On the other hand Oruka Therapeutics has an analysts' consensus of $43.17 which suggests that it could grow by 116.16%. Given that Oruka Therapeutics has higher upside potential than Streamline Health Solutions, analysts believe Oruka Therapeutics is more attractive than Streamline Health Solutions.
Company Buy Ratings Hold Ratings Sell Ratings STRMStreamline Health Solutions1 0 0 ORKAOruka Therapeutics6 0 0 -
Is STRM or ORKA More Risky?
Streamline Health Solutions has a beta of 1.552, which suggesting that the stock is 55.205% more volatile than S&P 500. In comparison Oruka Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock STRM or ORKA?
Streamline Health Solutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oruka Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Streamline Health Solutions pays -- of its earnings as a dividend. Oruka Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STRM or ORKA?
Streamline Health Solutions quarterly revenues are $4.4M, which are larger than Oruka Therapeutics quarterly revenues of --. Streamline Health Solutions's net income of -$2.5M is higher than Oruka Therapeutics's net income of -$28.6M. Notably, Streamline Health Solutions's price-to-earnings ratio is -- while Oruka Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Streamline Health Solutions is 0.78x versus -- for Oruka Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STRMStreamline Health Solutions0.78x -- $4.4M -$2.5M ORKAOruka Therapeutics-- -- -- -$28.6M
-
Which has Higher Returns STRM or TBRG?
TruBridge has a net margin of -56.03% compared to Streamline Health Solutions's net margin of -11.7%. Streamline Health Solutions's return on equity of -54.79% beat TruBridge's return on equity of -31.4%.
Company Gross Margin Earnings Per Share Invested Capital STRMStreamline Health Solutions46.03% -$0.61 $26.2M TBRGTruBridge49.46% -$0.66 $348.9M -
What do Analysts Say About STRM or TBRG?
Streamline Health Solutions has a consensus price target of $22.50, signalling downside risk potential of -59.02%. On the other hand TruBridge has an analysts' consensus of $15.60 which suggests that it could fall by -19.6%. Given that Streamline Health Solutions has more downside risk than TruBridge, analysts believe TruBridge is more attractive than Streamline Health Solutions.
Company Buy Ratings Hold Ratings Sell Ratings STRMStreamline Health Solutions1 0 0 TBRGTruBridge1 3 0 -
Is STRM or TBRG More Risky?
Streamline Health Solutions has a beta of 1.552, which suggesting that the stock is 55.205% more volatile than S&P 500. In comparison TruBridge has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.412%.
-
Which is a Better Dividend Stock STRM or TBRG?
Streamline Health Solutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TruBridge offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Streamline Health Solutions pays -- of its earnings as a dividend. TruBridge pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios STRM or TBRG?
Streamline Health Solutions quarterly revenues are $4.4M, which are smaller than TruBridge quarterly revenues of $83.8M. Streamline Health Solutions's net income of -$2.5M is higher than TruBridge's net income of -$9.8M. Notably, Streamline Health Solutions's price-to-earnings ratio is -- while TruBridge's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Streamline Health Solutions is 0.78x versus 0.84x for TruBridge. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income STRMStreamline Health Solutions0.78x -- $4.4M -$2.5M TBRGTruBridge0.84x -- $83.8M -$9.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Booking Holdings Stock Undervalued?
There is a lot of humdrum in the market about…
Broadcom vs American Express: Which Is Best?
Chip giant Broadcom Inc. (NASDAQ:AVGO) and card company American Express…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 116x
Sell
43
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Sell
47
DRUG alert for Jan 3
Bright Minds Biosciences [DRUG] is down 4.28% over the past day.
Buy
88
BMA alert for Jan 3
Banco Macro SA [BMA] is up 0.88% over the past day.
Sell
50
AGFY alert for Jan 3
Agrify [AGFY] is down 5.86% over the past day.
